Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate
- 1 July 2001
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 76 (1) , 25-31
- https://doi.org/10.1016/s0015-0282(01)01828-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Low-potency oestrogen and risk of endometrial cancer: a case-control studyThe Lancet, 1999
- Risk of Endometrial Cancer in Relation to Use of Low-Dose, Unopposed EstrogensObstetrics & Gynecology, 1998
- Effects of Hormone Replacement Therapy on Endometrial Histology in Postmenopausal WomenJAMA, 1996
- Hormone replacement therapy and endometrial cancer risk: A meta-analysisObstetrics & Gynecology, 1995
- Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens aloneAmerican Journal of Obstetrics and Gynecology, 1994
- Observer variability in endometrial cytology using kappa statistics.Journal of Clinical Pathology, 1992
- Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.BMJ, 1989
- Endometrial hyperplasia in women on cyclic or continuous estrogen regimensFertility and Sterility, 1982
- Replacement Estrogens and Endometrial CancerNew England Journal of Medicine, 1979
- Estrogens and Endometrial Cancer in a Retirement CommunityNew England Journal of Medicine, 1976